Publications by authors named "K A Kerber"
Repositioning maneuvers for benign paroxysmal positional vertigo (BPPV) designed to induce otoconial movement in one canal can trigger and sometimes unwittingly treat BPPV in other canals. Patients with BPPV are best managed by precisely diagnosing the canal variant and using correctly performed, standardized testing and treatment maneuvers.
View Article and Find Full Text PDFArticle Synopsis
- A study analyzed medication cost trends for five common neurological conditions from 2012 to 2021, focusing on out-of-pocket (OOP) and total costs for patients.
- The research found significant increases in OOP costs, particularly a 217% rise for MS medications, while generic medications led to notable decreases in costs for other conditions after their introduction.
- The findings suggest that using generic medications can reduce costs, except for MS, indicating a need for policy interventions like cost caps to manage rising expenses.
Background: Vertigo and dizziness can be disabling symptoms that result in sick leave. Research regarding sickness absence due to dizziness has focused on specific vestibular diagnoses rather than the nonspecific vertigo/dizziness diagnoses. Strict sick leave regulations were introduced in Sweden in 2008.
View Article and Find Full Text PDFBackground: Treatment with corticosteroids is common for patients with idiopathic and multiple sclerosis-associated optic neuritis (I/MS-ON). Yet, the Optic Neuritis Treatment Trial and meta-analyses confirm that few patients benefit and that visual benefit is of questionable clinical significance, short-lived, and comes with potential harms. The purpose of this study was to uncover the breadth of factors that underlie clinicians' treatment decisions and determine how these factors may influence corticosteroid use for I/MS-ON.
View Article and Find Full Text PDFObjective: Optic neuritis (ON) is an acute focal inflammation of the optic nerve routinely treated with glucocorticoids. We aimed to compare adverse events (AE) among glucocorticoid-treated and untreated patients in the real world to guide clinical decision making about treatment tradeoffs.
Design: Retrospective, longitudinal cohort study.